Clinical Trial Update: A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating Enicepatide (RO7795068) for obesity/overweight without type 2 diabetes; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Enicepatide (Enicepatide)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Obesity or Overweight | Phase 3 | Status: RECRUITING